Lilly-linked tirzepatide alopecia trial joins mazisotine results, eloralintide recruiting
Johns Hopkins registered a tirzepatide trial for scarring hair loss with Lilly support, alongside prior mazisotine results and recruiting eloralintide study.
Three Eli Lilly-linked studies had updates this week, including a newly registered trial from an academic collaborator.
- Tirzepatide (Mounjaro, Zepbound, LY3298176), a Phase 2 study sponsored by Johns Hopkins University with Eli Lilly as a collaborator, is recruiting to test whether the drug can treat active central centrifugal cicatricial alopecia (CCCA), a type of permanent scarring hair loss, in adults.1 The trial plans to enroll 20 participants who will self-administer tirzepatide by subcutaneous injection once weekly for 12 months.1
- Mazisotine (LY3556050), tested in a Phase 2 study for diabetic peripheral neuropathic pain, had results posted on 2026-07-30 after the study was designed to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP).2 The trial Enrollment: 404 participants (actual)2 across placebo and three mazisotine dose arms.
- Eloralintide (LY3841136), a Phase 1 study in participants with obesity or overweight, continues recruiting. The study's main purpose is to find out how significantly Eloralintide slows stomach emptying in participants who are overweight or obese3, with enrollment estimated at 56 participants.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.